A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

NCT00090532

Last updated date
Study Location
Pfizer Investigational Site
Mesa, Arizona, , United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Age-Related Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
55 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and/or female subjects >=55 years of age

- Subfoveal choroidal neovascularization complicating age-related macular degeneration

- Subjects who are informed of, and willing and able to comply with, the investigational nature of the study and are able to provide written informed consent in accordance with institutional and regulatory guidelines

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Other serious ocular diseases or conditions, including diabetic retinopathy and
glaucoma, that are likely to compromise visual acuity within 1 year

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Age-Related Macular DegenerationA Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration NCT00090532
  1. Mesa, Arizona
  2. Oro Valley, Arizona
  3. Phoenix, Arizona
  4. Sun City, Arizona
  5. Tucson, Arizona
  6. Tuscon, Arizona
  7. Beverly Hills, California
  8. Fort Myers, Florida
  9. Tampa, Florida
  10. Iowa City, Iowa
  11. Chevy Chase, Maryland
  12. Hagerstown, Maryland
  13. Boston, Massachusetts
  14. Ann Arbor, Michigan
  15. Livonia, Michigan
  16. Rochester, Michigan
  17. Royal Oak, Michigan
  18. St. Clair Shores, Michigan
  19. Ypsilanti, Michigan
  20. Slingerlands, New York
  21. Charlotte, North Carolina
  22. Huntersville, North Carolina
  23. Cleveland, Ohio
  24. Lakewood, Ohio
  25. Portland, Oregon
  26. Chambersburg, Pennsylvania
  27. Columbia, South Carolina
  28. Knoxville, Tennessee
  29. Houston, Texas
  30. Fairfax, Virginia
  31. Sydney, New South Wales
  32. East Melbourne, Victoria
  33. Nijmegen, Gld
  34. Groningen, GR
  35. Amsterdam, NH
  36. Rotterdam, ZH
  37. Aberdeen, Scotland
  38. Bristol,
  39. London,
ALL GENDERS
55 Years+
years
MULTIPLE SITES
Age-related Macular DegenerationLong-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice NCT00787319
  1. Brno,
  2. Brno,
  3. Olomouc,
  4. Olomouc,
  5. Ostrava - Poruba,
  6. Plzen,
  7. Praha 2,
  8. Praha 2,
  9. Praha 6,
  10. Praha 6,
  11. Usti nad Labem,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
Official Title  ICMJE A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety an Efficacy of AG-013958 in Subjects With Subfoveal Choroidal Neovascularization Associated With Age-related Macular Degeneration
Brief Summary AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial. Subjects will be male or female at least 55 years of age with "wet" age-related macular degeneration.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Age-Related Macular Degeneration
Intervention  ICMJE Drug: AG-013,958
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: September 2, 2005)
155
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE August 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and/or female subjects >=55 years of age
  • Subfoveal choroidal neovascularization complicating age-related macular degeneration
  • Subjects who are informed of, and willing and able to comply with, the investigational nature of the study and are able to provide written informed consent in accordance with institutional and regulatory guidelines

Exclusion Criteria:

  • Other serious ocular diseases or conditions, including diabetic retinopathy and glaucoma, that are likely to compromise visual acuity within 1 year
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 55 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Netherlands,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00090532
Other Study ID Numbers  ICMJE A4321001
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP